Propanc Biopharma, Inc. Common Stock (PPCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has a cash flow conversion efficiency ratio of -0.096x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-999.14K) by net assets ($10.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Propanc Biopharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Propanc Biopharma, Inc. Common Stock for a breakdown of total debt and financial obligations.
Propanc Biopharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
-0.004x |
|
Luxbright AB
ST:LXB
|
-0.321x |
|
CPT GLOBAL LTD
F:714
|
N/A |
|
Fluicell AB
ST:FLUI
|
-0.114x |
|
AFC Energy plc
LSE:AFC
|
-0.349x |
|
Nextferm Technologies Ltd
TA:NXFR
|
N/A |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
1.063x |
|
Constellation Technologies Ltd
AU:CT1
|
0.038x |
Annual Cash Flow Conversion Efficiency for Propanc Biopharma, Inc. Common Stock (2010–2025)
The table below shows the annual cash flow conversion efficiency of Propanc Biopharma, Inc. Common Stock from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Propanc Biopharma, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.91 Million | $-405.17K | -0.029x | -111.77% |
| 2024-06-30 | $-3.78 Million | $-935.12K | 0.247x | -30.21% |
| 2023-06-30 | $-3.12 Million | $-1.11 Million | 0.355x | -25.36% |
| 2022-06-30 | $-3.02 Million | $-1.44 Million | 0.475x | +27.23% |
| 2021-06-30 | $-3.07 Million | $-1.15 Million | 0.373x | -26.50% |
| 2020-06-30 | $-3.64 Million | $-1.85 Million | 0.508x | +6.05% |
| 2019-06-30 | $-4.30 Million | $-2.06 Million | 0.479x | +48.50% |
| 2018-06-30 | $-6.75 Million | $-2.18 Million | 0.323x | -18.43% |
| 2017-06-30 | $-5.44 Million | $-2.15 Million | 0.395x | -78.87% |
| 2016-06-30 | $-2.57 Million | $-4.80 Million | 1.871x | +300.52% |
| 2015-06-30 | $-3.05 Million | $-1.43 Million | 0.467x | +190.54% |
| 2014-06-30 | $-1.41 Million | $-226.44K | 0.161x | -0.95% |
| 2013-06-30 | $-792.48K | $-128.65K | 0.162x | -48.72% |
| 2012-06-30 | $-537.92K | $-170.28K | 0.317x | +338.36% |
| 2011-06-30 | $10.51 Million | $-1.40 Million | -0.133x | -112.96% |
| 2010-06-30 | $-186.90K | $-191.51K | 1.025x | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more